Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 5/20 | 0.58 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052110 | 0.89 | CYP1A2 (0.60) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL18424173 | 0.85 | CYP1A2 (0.73) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL26042174 | 0.85 | CYP1A2 (0.69) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL1734128 | 0.84 | MGLL (0.63) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL640619 | 0.84 | CYP1A2 (0.76) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL3996605 | 0.81 | MGLL (0.63) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL13397890 | 0.81 | CYP1A2 (0.61) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL1333584 | 0.81 | CYP1A2 (0.61) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL1052047 | 0.81 | CYP1A2 (0.61) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL1115881 | 0.81 | CYP1A2 (0.64) | CYP1A2CYP2D6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722662-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | MAOB, SLC6A4, SLC6A2 | CYP1A2 138/4885CYP2D6 44/4885MGLL 3744/4885 |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | SLC6A2, MAOB, MAOA | CYP1A2 93/4885CYP2D6 68/4885MGLL 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.